An experimental study using the Kras/Apc/Trp53 mouse model and human CRC tissues demonstrated that oncogenic Kras promoted MDSC migration and decreased T cell infiltration into the CRC microenvironment by inhibiting interferon regulatory factor 2 (IRF2) expression and subsequently activating Cxcl314. The gene discussed is KRAS; the disease is colorectal carcinoma.